ABT-126: Clinical Trials

9 trials of ABT-126, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 3 terminated. 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 29Completed 6, Terminated 3

Follow ABT-126: new trials by email Literature Review of ABT-126 trials Research Report on ABT-126

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)
ABT-126 - Schizophrenia
Phase 2TerminatedAbbVie2682013-03-012018-05-02
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
ABT-126 - Alzheimer's Disease
Phase 2TerminatedAbbVie (prior sponsor, Abbott)3432012-09-012021-08-02
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
ABT-126, Placebo - Schizophrenia
Phase 2CompletedAbbVie (prior sponsor, Abbott)1572012-08-012021-07-07
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
ABT-126 - Alzheimer's Disease
Phase 2TerminatedAbbVie (prior sponsor, Abbott)3492012-08-012021-08-02
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
ABT-126, Placebo - Schizophrenia
Phase 2CompletedAbbVie (prior sponsor, Abbott)4322012-05-012021-07-07
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
ABT-126, placebo - Alzheimer's Disease
Phase 2CompletedAbbVie (prior sponsor, Abbott)4342012-03-012014-10-31
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
placebo, donepezil, ABT-126 - Alzheimer's Disease
Phase 2CompletedAbbVie (prior sponsor, Abbott)4382012-02-012014-11-19
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia
ABT-126, Placebo - Cognitive Deficits in Schizophrenia
Phase 2CompletedAbbVie (prior sponsor, Abbott)2072010-03-012018-06-06
Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease
Placebo, ABT-126, donepezil - Alzheimer's Disease
Phase 2CompletedAbbVie (prior sponsor, Abbott)2742009-10-012013-01-31

Conditions studied

Alzheimer Disease (5)  ·  Schizophrenia (3)

Sponsors

AbbVie (prior sponsor, Abbott) (8)  ·  AbbVie (1)

Countries

United States (9)  ·  United Kingdom (7)  ·  South Africa (5)  ·  Russia (4)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Greece (2)  ·  Poland (2)  ·  Ukraine (2)  ·  Bulgaria (1)  ·  Czechia (1)  ·  Slovakia (1)

Top investigators

Laura Gault, MD (5)  ·  George Haig, PharmD (4)

Results publications

PMID 28433500, PMID 26967214, PMID 27319970, PMID 27756421, PMID 28223265, PMID 28922590, PMID 29854928

NIH funding

2009 (1)